Cellectar Biosciences Inc (NASDAQ: CLRB) on Friday, plunged -11.59% from the previous trading day, before settling in for the closing price of $0.41. Within the past 52 weeks, CLRB’s price has moved between $0.22 and $3.42.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 53.01%. With a float of $45.31 million, this company’s outstanding shares have now reached $46.08 million.
Let’s look at the performance matrix of the company that is accounted for 11 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cellectar Biosciences Inc (CLRB) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cellectar Biosciences Inc is 1.67%, while institutional ownership is 11.42%. The most recent insider transaction that took place on Jan 10 ’25, was worth 8,400. In this transaction Chief Operating Officer of this company bought 30,000 shares at a rate of $0.28, taking the stock ownership to the 83,141 shares.
Cellectar Biosciences Inc (CLRB) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 53.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.07% during the next five years compared to 40.27% growth over the previous five years of trading.
Cellectar Biosciences Inc (NASDAQ: CLRB) Trading Performance Indicators
Cellectar Biosciences Inc (CLRB) is currently performing well based on its current performance indicators. A quick ratio of 2.47 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.63 in one year’s time.
Technical Analysis of Cellectar Biosciences Inc (CLRB)
Cellectar Biosciences Inc (NASDAQ: CLRB) saw its 5-day average volume 135.39 million, a positive change from its year-to-date volume of 7.57 million. As of the previous 9 days, the stock’s Stochastic %D was 38.01%. Additionally, its Average True Range was 0.05.
During the past 100 days, Cellectar Biosciences Inc’s (CLRB) raw stochastic average was set at 28.68%, which indicates a significant increase from 27.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 230.33% in the past 14 days, which was higher than the 115.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2814, while its 200-day Moving Average is $0.9534. Nevertheless, the first resistance level for the watch stands at $0.3949 in the near term. At $0.4290, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.4550. If the price goes on to break the first support level at $0.3348, it is likely to go to the next support level at $0.3088. The third support level lies at $0.2747 if the price breaches the second support level.
Cellectar Biosciences Inc (NASDAQ: CLRB) Key Stats
Market capitalization of the company is 16.63 million based on 46,080K outstanding shares. Right now, sales total 0 K and income totals -44,580 K. The company made 0 K in profit during its latest quarter, and -6,600 K in sales during its previous quarter.
